



IFN
Attorney's Docket No.: 07917-178001 / UMMC 03-14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jones et al. Art Unit : 1642
Serial No. : 10/719,054 Examiner : Joyce, Catherine
Filed : November 20, 2003
Title : DIAGNOSING AND TREATING HEMATOPOIETIC CANCERS

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

This statement is being filed before a first Office action on the merits.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

November 17, 2005

Date of Deposit

Mary J. Zyndre

Signature

Mary J. Zyndre

Typed or Printed Name of Person Signing Certificate


Applicant : Jones et al.
Serial No. : 10/719,054
Filed : November 20, 2003
Page : 2 of 2

Attorney's Docket No.: 07917-178001 / UMMC 03-14

Please apply any other charges or credits to Deposit Account No. 06-1050, referencing
Attorney Docket No. 07917-178001.

Respectfully submitted,

Date: 11-16-2005


Janice L. Kugler
Reg. No. 50,429

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906
21208416.doc

Substitute Form PTO-1449 (Modified) OCT 2001 NOV 21 2005 Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.96(b))		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-178001	Application No. 10/719,054
		Applicant Jones et al.		
		Filing Date November 20, 2003	Group Art Unit	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,215,051	Jul. 29, 1980	Schroeder, et al.			
	AB	4,522,811	June 11, 1985	Eppstein, et al.			
	AC	4,683,202	Jul. 28, 1987	Mullis			
	AD	4,868,103	Sept. 19, 1989	Stavrianopoulos, et al.			
	AE	5,223,409	June 29, 1993	Ladner, et al.			
	AF	5,272,071	Dec. 21, 1993	Chappel			
	AG	5,283,317	Feb. 1, 1994	Saifer, et al.			
	AH	5,328,470	Jul. 12, 1994	Nabel, et al.			
	AI	5,459,039	Oct. 17, 1995	Modrich, et al.			
	AJ	5,498,531	Mar. 12, 1996	Jarrell			
	AK	5,631,169	May 20, 1997	Lakowicz, et al.			
	AL	5,695,937	Dec. 9, 1997	Kinzler, et al.			
	AM	5,851,984	Dec. 22, 1998	Matthews et al.			
	AN	5,854,033	Dec. 29, 1998	Lizardi			
	AO	5,876,742	Mar. 2, 1999	Cochrume, et al.			
	AP	6,159,462	Dec. 12, 2000	Matthews et al.			
	AQ	20020049177	Apr. 25, 2002	Clark et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AR	WO 94/10300	05/11/04	WIPO				
	AS	WO 91/06667	05/16/91	WIPO				
	AT							
	AU							
	AV							
	AW							

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-178001	Application No. 10/719,054
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Jones et al.	
		Filing Date November 20, 2003	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	AX	Austin et al., "A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells," Blood 89(10):3624-635 (1997)	
	AY	Bai et al., Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector," Gene Ther. 10(17):1446-57 (2003)	
	AZ	Cavazzana-Calvo et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," Science 288(5466):669-72 (2000)	
	AAA	Fry and Mackall, "Interleukin-7: from bench to clinic," Blood 99(11):3892-904 (2002)	
	ABB	He et al., "A member of the frizzled protein family mediating axis induction by Wnt-5a," Science 275:652-654 (1997)	
	ACC	Holmen et al., "A novel set of Wnt-Frizzled fusion proteins identifies receptor components that activate beta-catenin-dependent signaling," J. Biol. Chem. 277(38):34727-35 (2002)	
	ADD	Iozzo et al., "Aberrant expression of the growth factor Wnt-5A in human malignancy," Cancer Res. 55(16):3495-499 (1995)	
	AEE	Jönsson et al., "Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas," Cancer Res. 62(2):409-16 (2002)	
	AFF	Jordan et al., "Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation," Exp. Hematol. 23:1011-1015 (1995)	
	AGG	Jurecic et al., "Enrichment and functional characterization of Sca-1 ⁺ WGA ⁺ , Lin-WGA ⁺ , Lin-Sca-1 ⁺ , and Lin-Sca-1 ⁺ WGA ⁺ bone marrow cells from mice with an Ly-6a haplotype," Blood 82(9):2673-83 (1993)	
	AHH	Kawakami et al., "WNT signals control FGF-dependent limb initiation and AER induction in the chick embryo," Cell 104(6):891-900 (2001)	
	AII	Kühl et al., "Ca ²⁺ /calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus," J. Biol. Chem. 275(17):12701-11 (2000)	
	AJJ	Kühl et al., "Antagonistic regulation of convergent extension movements in Xenopus by Wnt/beta-catenin and Wnt/Ca ²⁺ signaling," Mech Dev. 106(1-2):61-76 (2001)	
	AKK	Lejeune et al., "Wnt5a cloning, expression, and up-regulation in human primary breast cancers," Clin. Cancer Res 1(2):215-22 (1995)	
	ALL	Li and Johnson, "Murine hematopoietic stem and progenitor cells: I. Enrichment and biologic characterization," Blood 85(6):1472-9 (1995)	
	AMM	Liang et al., "Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue," Cancer Cell 4(5):349-60 (2003)	
	ANN	Liang et al., "A role for Wnt5a in B cell growth and tumorigenesis," Proc. Amer. Assoc. Cancer Research, Annual Meeting 43:667, Abstract #3310 (2002)	
	AOO	Olson et al., "Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a," Cell Growth Differ. 8(4):417-23 (1997)	
	APP	Phillips et al., "The genetic program of hematopoietic stem cells," Science 288(5471):1635-40 (2000)	
	AQQ	Rimerman et al., "Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation," J. Biol. Chem. 275(19):14736-42 (2000)	
	ARR	Schmidt-Wolf and Schmidt-Wolf, "Gene therapy for hematological malignancies," Clin. Exp. Med. 3(1):4-14 (2003)	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-178001	Application No. 10/719,054
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Jones et al.	
		Filing Date November 20, 2003	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ASS	Slusarski et al., "Modulation of embryonic intracellular Ca ²⁺ signaling by Wnt-5A," Dev. Biol. 182(1):114-20 (1997)
	ATT	Toyofuku et al., "Wnt/frizzled-2 signaling induces aggregation and adhesion among cardiac myocytes by increased cadherin-beta-catenin complex," J. Cell. Biol. 150(1):225-41 (2000)
	AUU	Van Den Berg et al., "Role of members of the Wnt gene family in human hematopoiesis," Blood 92(9):3189-202 (1998)
	AVV	Weeraratna et al., "Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma," Cancer Cell. 1 (3):279-88 (2002)
	AWW	Whitlock et al., "Murine B cell lymphopoiesis in long term culture," J. Immunol. Methods 67(2):353-69 (1984)
	AXX	Willert et al., "A transcriptional response to Wnt protein in human embryonic carcinoma cells," BMC Dev. Biol. 2(1):8. Epub 2002 Jul 02 (2002)
	AYY	Yamaguchi et al., "A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo," Development 126(6):1211-23 (1999)
	AZZ	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	